Abstract
BackgroundTocilizumab, an intravenous agent, is approved for rheumatoid arthritis (RA) treatment in Canada since April 30th, 2010. It was the sixth approved agent after adalimumab, etanercept, abatacept, infliximab and rituximab....
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
